ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1044

Alendronate-CGS21680 Conjugates Prevent Bone Erosion in a Murine Osteolysis Model

Ane Larrañaga Vera1, Kiran Toti2, Eugene Warnick2, Harsha Rao2, Zhan-Guo Gao2, Alexandra Gadiano2, Aranzazu Mediero3, Kenneth A. Jacobson2 and Bruce N. Cronstein4, 1Medicine, New York University School of Medicine, New York, NY, 2Molecular Recognition Section, NIDDK-NIH, Bethesda, MD, 3Joint and Bone Research Unit, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain, 4Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: adenosine receptors and prosthesis, Bone

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Osteoarthritis and Joint Biology – Basic Science Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

The most common cause of total joint replacement revision surgeries is loosening of the implant due to loss of bone around the prosthesis. Wear particles shed from the prosthesis plays a critical role by increasing local inflammation and osteoclast number and activity, ultimately causing osteolysis. We have previously reported that an A2A adenosine receptor selective agonist (CGS21680, CGS) prevents osteolysis in wear particle-induced osteolysis model in mice. Frequent administration requirements and potential toxicity make it a less than optimal treatment for inflammatory osteolysis. We therefore generated and tested a novel alendronate-CGS conjugate (MRS7216) that specifically localizes to bone targeting the agonist to the site of tissue injury and thereby diminishing the frequency of administration and curtailing systemic side effects.

Methods:

The conjugate was synthesized from CGS by sequential activation of the carboxylic acid moiety and reacting with the appropriate amino acid under basic conditions. A PEG6 linker was incorporated to alendronic acid by direct coupling. Osteolysis in 6–8-week-old C57BL/6J mice was induced by surgical implantation of 3mg of ultrahigh-molecular-weight-polyethylene particles over the calvaria. Mice received a weekly 10mg/kg intraperitoneal dose of MRS7216 conjugate, starting at the time of surgery. Other groups of mice were treated with equivalent weekly doses of alendronate-PEG6 (AlenP) or saline respectively. An additional control group underwent sham surgery. After 2 weeks, animals were sacrificed and microCT and histology analyses were performed. The studies were approved by the Institutional Animal Care and Use Committee of NYU School of Medicine.

Results:

Receptor binding studies demonstrate that the Ki for CGS, 7216 conjugates and the control AlenP molecules were 21.5 nM, 69.2 nM and >10,000 nM respectively, indicating that MRS7216 efficiently binds the A2A adenosine receptor. MicroCT studies showed that mice treated with weekly doses of 7216 had a significant reduction in bone damage of 40% (p=0.04) compared to saline treated mice. In contrast, AlenP molecules did not prevent bone erosion. Histological analysis of TRAP stained samples showed a significant decrease of osteoclast number/high-power field (HPF) of 55% (p=0.03) in AlenP treated mice compared to the saline treated group. The osteoclast depletion was more dramatic in MRS7216 treated group with an 81% reduction of osteoclasts number/HPF (p= 0.002). Additionally alkaline phosphatase staining in MRS7216 treated group, showed a significant increase in osteoblast number/HPF compared to saline (55%, p=0.01) and to AlenP group (45%, p=0.03).

Conclusion:

Alendronate-CGS conjugates represent a novel therapeutic approach to prevent osteolysis and prosthetic failure in patients with prosthetic joints.


Disclosure: A. Larrañaga Vera, None; K. Toti, None; E. Warnick, None; H. Rao, None; Z. G. Gao, None; A. Gadiano, None; A. Mediero, CP15/00053 PI16/0991, 2, 9; K. A. Jacobson, None; B. N. Cronstein, Cantic Biopharma, Regenosine, 1,NIH Arthitis foundation, Astrazeneca, 2,Horizon Pharmaceuticals, Regenosine, 5,Patent issued and pending, 9.

To cite this abstract in AMA style:

Larrañaga Vera A, Toti K, Warnick E, Rao H, Gao ZG, Gadiano A, Mediero A, Jacobson KA, Cronstein BN. Alendronate-CGS21680 Conjugates Prevent Bone Erosion in a Murine Osteolysis Model [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/alendronate-cgs21680-conjugates-prevent-bone-erosion-in-a-murine-osteolysis-model/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/alendronate-cgs21680-conjugates-prevent-bone-erosion-in-a-murine-osteolysis-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology